研究单位：[1]Chengdu Kanghong Biotech Co., Ltd.[2]Shanghai Tongji Hospital Shanghai, China[3]Shenyang the Fourth Hospital of People Shenyang, China[4]The Fourth Affiliated Hospital of China Medical University Shenyang, China[5]Peking University Shenzhen Hospital Shenzhen, China[6]Shenzhen Eye Hospital Shenzhen, China[7]The Second Hospital of Hebei Medical University Shijiazhuang, China[8]Shanxi Eye Hospital Taiyuan, China[9]Tianjin Medical University Eye Hospital Tianjin, China[10]Wuhan General Hospital of Pla Wuhan, China[11]No.474 Hospital of Pla Wulumuqi, China[12]Wuxi NO.2 People's Hospital Wuxi, China[13]Tangdu Hospital Xi'an, China[14]Xi'An No.4 Hospitla Xi'an, China[15]Xijing Hospital Xian, China[16]Hebeisheng Eye Hospital Xingtai, China[17]The First People's Hospital of Xuzhou Xuzhou, China[18]Zhongshan Ophthalmic Center, Sun Yay-Sen University Zhongshan, China[19]Shanghai General Hospital Shanghai, China[20]Shanghai Baoshan Hospital of Integrate Traditional Chinese and Western Medicine[21]Ningxia People'S Hospital Ningxia, China
研究目的：
This is a post-marketing drug safety monitoring study in a prospective manner, and data collection will be performed in a registration-follow-up manner. Safety information about patients who have received intravitreal injection of Conbercept Ophthalmic Injection in medical institutions involved in the study during research will be actively monitored without intervening in diagnosis and treatment. All patients enrolled will be followed up for one year.
